[10-Q] Arcturus Therapeutics Holdings Inc. Quarterly Earnings Report
Arcturus reported lower collaboration-driven revenue as its COVID-19 vaccine transitioned to commercialization, while advancing clinical programs and recognizing milestone payments.
Total revenue for the quarter was $28.3 million versus $49.9 million a year earlier, driven by $24.4 million of collaboration revenue from CSL Seqirus and $3.8 million of grant revenue from BARDA. Net loss was $9.18 million for the quarter and $23.26 million for the six months. Cash and restricted cash totaled $253.4 million, and the accumulated deficit was $472.1 million.
The company highlighted regulatory and commercial progress for KOSTAIVE (ARCT-154) with approvals in Japan and the EU, receipt of a $200.0 million upfront payment from CSL and approximately $509.7 million of total upfronts and milestones to date, including a $20.0 million development milestone recognized this quarter. Research and development and general and administrative expenses declined year-over-year as programs shifted toward commercialization.
Arcturus ha registrato un calo dei ricavi derivanti da collaborazioni mentre il suo vaccino COVID-19 è passato alla commercializzazione, continuando a far avanzare i programmi clinici e a contabilizzare pagamenti legati a milestone.
I ricavi totali del trimestre sono stati $28.3 million rispetto a $49.9 million dell'anno precedente, trainati da $24.4 million di ricavi da collaborazione con CSL Seqirus e $3.8 million di contributi da BARDA. La perdita netta è stata di $9.18 million nel trimestre e di $23.26 million nei sei mesi. La liquidità e la liquidità vincolata ammontavano a $253.4 million, mentre il disavanzo accumulato era di $472.1 million.
L'azienda ha evidenziato i progressi regolatori e commerciali per KOSTAIVE (ARCT-154), con approvazioni in Giappone e nell'UE, la ricezione di un pagamento iniziale di $200.0 million da CSL e circa $509.7 million di upfront e milestone complessivi fino ad oggi, incluso un milestone di sviluppo di $20.0 million riconosciuto in questo trimestre. I costi di ricerca e sviluppo e le spese generali e amministrative sono diminuiti su base annua con il passaggio dei programmi verso la commercializzazione.
Arcturus informó una reducción de los ingresos por colaboraciones al pasar su vacuna contra la COVID-19 a la comercialización, mientras avanzaba programas clínicos y registraba pagos por hitos.
Los ingresos totales del trimestre fueron de $28.3 million frente a $49.9 million del año anterior, impulsados por $24.4 million de ingresos por colaboración con CSL Seqirus y $3.8 million de subvenciones de BARDA. La pérdida neta fue de $9.18 million en el trimestre y de $23.26 million en seis meses. El efectivo y el efectivo restringido sumaron $253.4 million, y el déficit acumulado fue de $472.1 million.
La compañía destacó los avances regulatorios y comerciales para KOSTAIVE (ARCT-154), con aprobaciones en Japón y la UE, la recepción de un pago inicial de $200.0 million de CSL y aproximadamente $509.7 million en pagos iniciales y hitos acumulados hasta la fecha, incluido un hito de desarrollo de $20.0 million reconocido en este trimestre. Los gastos de investigación y desarrollo y los gastos generales y administrativos disminuyeron año tras año a medida que los programas se orientaron hacia la comercialización.
Arcturus는 자사의 COVID-19 백신이 상업화로 전환되면서 협업 기반 수익이 감소한 반면, 임상 프로그램을 진전시키고 마일스톤 지급을 인식했다고 보고했습니다.
분기 총수익은 $28.3 million으로 전년의 $49.9 million에 비해 감소했으며, 이는 CSL Seqirus로부터의 $24.4 million 협력 수익과 BARDA로부터의 $3.8 million 보조금에 기인합니다. 순손실은 분기 기준 $9.18 million, 6개월 기준 $23.26 million이었습니다. 현금 및 제한된 현금은 총 $253.4 million였고, 누적 적자는 $472.1 million였습니다.
회사는 KOSTAIVE (ARCT-154)의 규제 및 상업적 진전을 강조했으며, 일본 및 EU에서의 승인, CSL로부터의 $200.0 million 선지급 수령 및 현재까지 총 약 $509.7 million의 선지급·마일스톤을 확보했다고 밝혔습니다. 이 분기에는 $20.0 million의 개발 마일스톤이 인식되었습니다. 연구개발비와 일반관리비는 프로그램이 상업화로 전환되면서 전년 대비 감소했습니다.
Arcturus a déclaré une baisse des revenus issus de collaborations alors que son vaccin contre la COVID‑19 passait à la commercialisation, tout en faisant progresser des programmes cliniques et en comptabilisant des paiements liés à des jalons.
Le chiffre d'affaires total du trimestre s'est élevé à $28.3 million contre $49.9 million un an plus tôt, porté par $24.4 million de revenus de collaboration avec CSL Seqirus et $3.8 million de subventions de BARDA. La perte nette s'est établie à $9.18 million pour le trimestre et à $23.26 million sur six mois. Les liquidités et la trésorerie restreinte totalisaient $253.4 million, et le déficit cumulé était de $472.1 million.
La société a souligné les progrès réglementaires et commerciaux pour KOSTAIVE (ARCT-154), avec des autorisations au Japon et dans l'UE, la réception d'un acompte de $200.0 million de CSL et environ $509.7 million d'acomptes et de jalons cumulés à ce jour, y compris un jalon de développement de $20.0 million comptabilisé ce trimestre. Les dépenses de recherche et développement ainsi que les frais généraux et administratifs ont diminué d'une année sur l'autre, les programmes s'orientant vers la commercialisation.
Arcturus meldete niedrigere kollaborationsbedingte Umsätze, da sein COVID‑19‑Impfstoff in die Kommerzialisierung überging, während klinische Programme vorangetrieben und Meilensteinzahlungen verbucht wurden.
Der Gesamtumsatz im Quartal belief sich auf $28.3 million gegenüber $49.9 million im Vorjahr, getragen von $24.4 million Kollaborationsumsätzen mit CSL Seqirus und $3.8 million Zuschussumsätzen von BARDA. Der Nettoverlust betrug $9.18 million im Quartal und $23.26 million für die sechs Monate. Zahlungsmittel und gebundene Zahlungsmittel beliefen sich auf $253.4 million, und der kumulierte Fehlbetrag lag bei $472.1 million.
Das Unternehmen hob regulatorische und kommerzielle Fortschritte für KOSTAIVE (ARCT-154) hervor, einschließlich Zulassungen in Japan und der EU, den Eingang einer $200.0 million Vorauszahlung von CSL und insgesamt rund $509.7 million an Vorauszahlungen und Meilensteinen bis dato, darunter ein Entwicklungsmeilenstein von $20.0 million, der in diesem Quartal verbucht wurde. Forschungs‑ und Entwicklungskosten sowie allgemeine Verwaltungsaufwendungen gingen im Jahresvergleich zurück, da Programme in Richtung Kommerzialisierung verschoben wurden.
- KOSTAIVE (ARCT-154) received marketing authorization in Japan and the European Commission, validating the company's sa-mRNA platform.
- Company has received $200.0 million upfront from CSL Seqirus and reports approximately $509.7 million in total upfronts and milestones to date, including a $20.0 million milestone in the quarter.
- Cash and restricted cash of $253.4 million provides near-term liquidity support.
- ARCT-810 (OTC) showed positive multi-dose Phase 2 biomarker results across two studies, and ARCT-032 (CF) advanced into Phase 2 dosing.
- Total revenue declined 43% year-over-year for the quarter to $28.3 million, and declined 34% year-to-date to $57.7 million, driven by lower CSL collaboration supply and amortization revenue.
- Net cash used in operating activities was $40.9 million for the six months ended June 30, 2025.
- Accumulated deficit of $472.1 million reflects multi-year losses to date.
- $55.0 million of cash is restricted and pledged as collateral under the Wells Fargo credit agreement, limiting available liquidity.
Insights
TL;DR: Revenue fell sharply as development revenue declines offset milestone receipts; cash runway supported by CSL payments.
Revenue declined 43% year-over-year for the quarter to $28.3 million, largely due to lower supply and amortization revenue as KOSTAIVE transitions to commercial sales. Operating expenses fell materially, with R&D down to $29.6 million for the quarter from $58.7 million a year ago. Net cash used in operations was $40.9 million for six months. Cash plus restricted cash of $253.4 million and milestone receipts (including a $20.0 million milestone this quarter and a prior $200.0 million upfront) are primary near-term liquidity supports.
TL;DR: Regulatory approvals and positive clinical signals increase product and platform validation.
KOSTAIVE (ARCT-154) achieved marketing authorizations in Japan and the EU, and recent clinical and safety publications reported no new safety signals in large trials. ARCT-810 (OTC) reported positive multi-dose Phase 2 biomarker results across studies, and ARCT-032 (CF) advanced to Phase 2 dosing. These developments substantiate the STARR and LUNAR platforms and underpin potential future collaboration and royalty streams under the CSL Seqirus agreement.
Arcturus ha registrato un calo dei ricavi derivanti da collaborazioni mentre il suo vaccino COVID-19 è passato alla commercializzazione, continuando a far avanzare i programmi clinici e a contabilizzare pagamenti legati a milestone.
I ricavi totali del trimestre sono stati $28.3 million rispetto a $49.9 million dell'anno precedente, trainati da $24.4 million di ricavi da collaborazione con CSL Seqirus e $3.8 million di contributi da BARDA. La perdita netta è stata di $9.18 million nel trimestre e di $23.26 million nei sei mesi. La liquidità e la liquidità vincolata ammontavano a $253.4 million, mentre il disavanzo accumulato era di $472.1 million.
L'azienda ha evidenziato i progressi regolatori e commerciali per KOSTAIVE (ARCT-154), con approvazioni in Giappone e nell'UE, la ricezione di un pagamento iniziale di $200.0 million da CSL e circa $509.7 million di upfront e milestone complessivi fino ad oggi, incluso un milestone di sviluppo di $20.0 million riconosciuto in questo trimestre. I costi di ricerca e sviluppo e le spese generali e amministrative sono diminuiti su base annua con il passaggio dei programmi verso la commercializzazione.
Arcturus informó una reducción de los ingresos por colaboraciones al pasar su vacuna contra la COVID-19 a la comercialización, mientras avanzaba programas clínicos y registraba pagos por hitos.
Los ingresos totales del trimestre fueron de $28.3 million frente a $49.9 million del año anterior, impulsados por $24.4 million de ingresos por colaboración con CSL Seqirus y $3.8 million de subvenciones de BARDA. La pérdida neta fue de $9.18 million en el trimestre y de $23.26 million en seis meses. El efectivo y el efectivo restringido sumaron $253.4 million, y el déficit acumulado fue de $472.1 million.
La compañía destacó los avances regulatorios y comerciales para KOSTAIVE (ARCT-154), con aprobaciones en Japón y la UE, la recepción de un pago inicial de $200.0 million de CSL y aproximadamente $509.7 million en pagos iniciales y hitos acumulados hasta la fecha, incluido un hito de desarrollo de $20.0 million reconocido en este trimestre. Los gastos de investigación y desarrollo y los gastos generales y administrativos disminuyeron año tras año a medida que los programas se orientaron hacia la comercialización.
Arcturus는 자사의 COVID-19 백신이 상업화로 전환되면서 협업 기반 수익이 감소한 반면, 임상 프로그램을 진전시키고 마일스톤 지급을 인식했다고 보고했습니다.
분기 총수익은 $28.3 million으로 전년의 $49.9 million에 비해 감소했으며, 이는 CSL Seqirus로부터의 $24.4 million 협력 수익과 BARDA로부터의 $3.8 million 보조금에 기인합니다. 순손실은 분기 기준 $9.18 million, 6개월 기준 $23.26 million이었습니다. 현금 및 제한된 현금은 총 $253.4 million였고, 누적 적자는 $472.1 million였습니다.
회사는 KOSTAIVE (ARCT-154)의 규제 및 상업적 진전을 강조했으며, 일본 및 EU에서의 승인, CSL로부터의 $200.0 million 선지급 수령 및 현재까지 총 약 $509.7 million의 선지급·마일스톤을 확보했다고 밝혔습니다. 이 분기에는 $20.0 million의 개발 마일스톤이 인식되었습니다. 연구개발비와 일반관리비는 프로그램이 상업화로 전환되면서 전년 대비 감소했습니다.
Arcturus a déclaré une baisse des revenus issus de collaborations alors que son vaccin contre la COVID‑19 passait à la commercialisation, tout en faisant progresser des programmes cliniques et en comptabilisant des paiements liés à des jalons.
Le chiffre d'affaires total du trimestre s'est élevé à $28.3 million contre $49.9 million un an plus tôt, porté par $24.4 million de revenus de collaboration avec CSL Seqirus et $3.8 million de subventions de BARDA. La perte nette s'est établie à $9.18 million pour le trimestre et à $23.26 million sur six mois. Les liquidités et la trésorerie restreinte totalisaient $253.4 million, et le déficit cumulé était de $472.1 million.
La société a souligné les progrès réglementaires et commerciaux pour KOSTAIVE (ARCT-154), avec des autorisations au Japon et dans l'UE, la réception d'un acompte de $200.0 million de CSL et environ $509.7 million d'acomptes et de jalons cumulés à ce jour, y compris un jalon de développement de $20.0 million comptabilisé ce trimestre. Les dépenses de recherche et développement ainsi que les frais généraux et administratifs ont diminué d'une année sur l'autre, les programmes s'orientant vers la commercialisation.
Arcturus meldete niedrigere kollaborationsbedingte Umsätze, da sein COVID‑19‑Impfstoff in die Kommerzialisierung überging, während klinische Programme vorangetrieben und Meilensteinzahlungen verbucht wurden.
Der Gesamtumsatz im Quartal belief sich auf $28.3 million gegenüber $49.9 million im Vorjahr, getragen von $24.4 million Kollaborationsumsätzen mit CSL Seqirus und $3.8 million Zuschussumsätzen von BARDA. Der Nettoverlust betrug $9.18 million im Quartal und $23.26 million für die sechs Monate. Zahlungsmittel und gebundene Zahlungsmittel beliefen sich auf $253.4 million, und der kumulierte Fehlbetrag lag bei $472.1 million.
Das Unternehmen hob regulatorische und kommerzielle Fortschritte für KOSTAIVE (ARCT-154) hervor, einschließlich Zulassungen in Japan und der EU, den Eingang einer $200.0 million Vorauszahlung von CSL und insgesamt rund $509.7 million an Vorauszahlungen und Meilensteinen bis dato, darunter ein Entwicklungsmeilenstein von $20.0 million, der in diesem Quartal verbucht wurde. Forschungs‑ und Entwicklungskosten sowie allgemeine Verwaltungsaufwendungen gingen im Jahresvergleich zurück, da Programme in Richtung Kommerzialisierung verschoben wurden.
cs
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number:
(Exact Name of Registrant as Specified in its Charter)
|
||
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer |
|
|
|
(Address of principal executive offices) |
|
(Zip Code) |
(
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
|
☐ |
|
|
☒ |
|
|
|
|
|
|||
Non-accelerated filer |
|
☐ |
|
Smaller reporting company |
|
|
|
|
|
|
|
|
|
Emerging growth company |
|
|
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As of August 8, 2025, the registrant had
ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES
TABLE OF CONTENTS
|
|
Page |
PART I. |
FINANCIAL INFORMATION |
1 |
Item 1. |
Financial Statements (unaudited) |
1 |
|
Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 |
1 |
|
Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 |
2 |
|
Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and six months ended June 30, 2025 and 2024 |
3 |
|
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 |
4 |
|
Notes to Condensed Consolidated Financial Statements |
5 |
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
14 |
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
23 |
Item 4. |
Controls and Procedures |
23 |
PART II. |
OTHER INFORMATION |
25 |
Item 1. |
Legal Proceedings |
25 |
Item 1A. |
Risk Factors |
25 |
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds |
25 |
Item 3. |
Defaults Upon Senior Securities |
25 |
Item 4. |
Mine Safety Disclosures |
25 |
Item 5. |
Other Information |
25 |
Item 6. |
Exhibits |
26 |
Signatures |
29 |
|
i
Special Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q (this “Quarterly Report”), including the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and the documents incorporated by reference herein may contain express or implied “forward-looking statements” within the meaning of the federal securities laws, Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under Part II, Item 1A, “Risk Factors” in this Quarterly Report. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent our current expectations or beliefs concerning various future events, may contain words such as “may,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate” or other words indicating future results, though not all forward-looking statements necessarily contain these identifying words. Such statements may include, but are not limited to, statements concerning the following:
ii
These and other forward-looking statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. In addition, historic results of scientific research, preclinical and clinical trials do not guarantee that future research or trials will suggest the same conclusions, nor that historic results referred to herein will be interpreted in the same manner due to additional research, preclinical and clinical trial results or otherwise. The forward-looking statements contained in this Quarterly Report are subject to risks and uncertainties, including those discussed in our other filings with the United States Securities and Exchange Commission (the “Commission”). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof unless specifically stated otherwise. Although we currently believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
iii
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
|
|
June 30, |
|
|
December 31, |
|
||
(in thousands, except par value information) |
|
(unaudited) |
|
|
|
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
|
|
$ |
|
||
Restricted cash |
|
|
|
|
|
|
||
Accounts receivable |
|
|
|
|
|
|
||
Prepaid expenses and other current assets |
|
|
|
|
|
|
||
Total current assets |
|
|
|
|
|
|
||
Property and equipment, net |
|
|
|
|
|
|
||
Operating lease right-of-use assets, net |
|
|
|
|
|
|
||
Non-current restricted cash |
|
|
|
|
|
|
||
Total assets |
|
$ |
|
|
$ |
|
||
Liabilities and stockholders’ equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
|
|
$ |
|
||
Accrued liabilities |
|
|
|
|
|
|
||
Deferred revenue |
|
|
|
|
|
|
||
Total current liabilities |
|
|
|
|
|
|
||
Deferred revenue, net of current portion |
|
|
|
|
|
|
||
Operating lease liability, net of current portion |
|
|
|
|
|
|
||
Total liabilities |
|
|
|
|
|
|
||
Stockholders’ equity |
|
|
|
|
|
|
||
Common stock, $ |
|
|
|
|
|
|
||
Additional paid-in capital |
|
|
|
|
|
|
||
Accumulated deficit |
|
|
( |
) |
|
|
( |
) |
Total stockholders’ equity |
|
|
|
|
|
|
||
Total liabilities and stockholders’ equity |
|
$ |
|
|
$ |
|
||
The accompanying notes are an integral part of these condensed consolidated financial statements.
1
ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
June 30, |
|
|
June 30, |
|
||||||||||
(in thousands, except per share data) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Collaboration revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Grant revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development, net |
|
|
|
|
|
|
|
|
|
|
|
|
||||
General and administrative |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Loss from operations |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Loss from foreign currency |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Finance income, net |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss before income taxes |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Provision (benefit) for income taxes |
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|||
Net loss |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Net loss per share, basic and diluted |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Weighted-average shares outstanding, basic and diluted |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Comprehensive loss |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
The accompanying notes are an integral part of these condensed consolidated financial statements.
2
ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(unaudited)
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
|
Total |
|
|||||
|
|
Common Stock |
|
|
Paid-In |
|
|
Accumulated |
|
|
Stockholders’ |
|
||||||||
(in thousands) |
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Equity |
|
|||||
Balance – December 31, 2024 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||||
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Share-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
||
Issuance of common stock upon exercise of stock options |
|
|
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|||
Balance – March 31, 2025 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||||
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Share-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
||
Issuance of common stock upon exercise of stock options |
|
|
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|||
Balance at June 30, 2025 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||||
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
|
Total |
|
|||||
|
|
Common Stock |
|
|
Paid-In |
|
|
Accumulated |
|
|
Stockholders’ |
|
||||||||
(in thousands) |
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Equity |
|
|||||
Balance – December 31, 2023 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||||
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Share-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
||
Issuance of common stock upon exercise of stock options |
|
|
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|||
Balance – March 31, 2024 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||||
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Share-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
||
Issuance of common stock upon exercise of stock options |
|
|
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|||
Balance at June 30, 2024 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
|
|
Six Months Ended June 30, |
|
|||||
(in thousands) |
|
2025 |
|
|
2024 |
|
||
Operating activities |
|
|
|
|
|
|
||
Net loss |
|
$ |
( |
) |
|
$ |
( |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
||
Depreciation and amortization |
|
|
|
|
|
|
||
Share-based compensation expense |
|
|
|
|
|
|
||
Foreign currency transaction loss |
|
|
|
|
|
|
||
Changes in assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
( |
) |
|
|
|
|
Prepaid expense and other assets |
|
|
|
|
|
( |
) |
|
Right-of-use assets |
|
|
|
|
|
|
||
Accounts payable |
|
|
|
|
|
|
||
Accrued liabilities |
|
|
( |
) |
|
|
|
|
Deferred revenue |
|
|
( |
) |
|
|
( |
) |
Lease liabilities |
|
|
( |
) |
|
|
( |
) |
Net cash used in operating activities |
|
|
( |
) |
|
|
( |
) |
Investing activities |
|
|
|
|
|
|
||
Acquisition of property and equipment |
|
|
( |
) |
|
|
( |
) |
Net cash used in investing activities |
|
|
( |
) |
|
|
( |
) |
Financing activities |
|
|
|
|
|
|
||
Proceeds from exercise of stock options |
|
|
|
|
|
|
||
Proceeds from debt |
|
|
|
|
|
— |
|
|
Payments on debt obligations |
|
|
( |
) |
|
|
— |
|
Net cash provided by financing activities |
|
|
|
|
|
|
||
Net decrease in cash, cash equivalents and restricted cash |
|
|
( |
) |
|
|
( |
) |
Cash, cash equivalents and restricted cash at beginning of the period |
|
|
|
|
|
|
||
Cash, cash equivalents and restricted cash at end of the period |
|
$ |
|
|
$ |
|
||
|
|
Six Months Ended June 30, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Non-cash investing activities |
|
|
|
|
|
|
||
Non-cash asset disposal |
|
$ |
— |
|
|
$ |
|
|
Right-of-use assets acquired through operating leases |
|
$ |
— |
|
|
$ |
|
|
|
|
|
|
|
|
|
||
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1. Description of Business, Basis of Presentation and Summary of Significant Accounting Policies
Description of Business
Arcturus Therapeutics Holdings Inc. (the “Company” or "Arcturus") is a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines. Arcturus became a clinical stage company in 2020 when it announced that its Investigational New Drug (“IND”) application for ornithine transcarbamylase (“OTC”) deficiency and its Clinical Trial Application (“CTA”) for candidate LUNAR-COV19 were approved by applicable health authorities. In 2023, our COVID-19 vaccine, ARCT-154 (also referred to as KOSTAIVE®), received marketing authorization approval in Japan for
Basis of Presentation
The accompanying condensed consolidated financial statements include the accounts of Arcturus and its subsidiaries and are unaudited. All intercompany accounts and transactions have been eliminated in consolidation. These condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.
Interim financial results are not necessarily indicative of results anticipated for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.
These condensed consolidated financial statements are prepared in accordance with GAAP, which requires management to make estimates and assumptions regarding the valuation of certain debt and equity instruments, share-based compensation, accruals for liabilities, income taxes, revenue and deferred revenue, leases, and other matters that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on management’s knowledge of current events and actions the Company may undertake in the future, actual results may ultimately differ from these estimates and assumptions.
There were no significant changes to our significant accounting policies as disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.
Recently Issued Accounting Standards Not Yet Adopted
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the condensed consolidated financial statements and disclosures.
In November 2024, the FASB issued ASU 2024-03, Income Statement–Reporting Comprehensive Income–Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires public entities to disclose specified information about certain costs and expenses on an interim and annual basis. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact that adoption of ASU 2024-03 will have on the financial statement disclosures.
5
Note 2. Revenue
The Company has entered into license agreements and collaborative research and development arrangements with pharmaceutical and biotechnology companies, as well as consulting, related technology transfer, product revenue and government grant agreements. Under these arrangements, the Company is entitled to receive license fees, consulting fees, product fees, technological transfer fees, upfront payments, milestone payments if and when certain research and development milestones, technology transfer milestones or success-based milestones are achieved, royalties on approved product sales and reimbursement for research and development activities. The Company’s costs of performing these services are included within research and development expenses. The Company’s milestone payments are typically defined by achievement of certain preclinical, clinical, and commercial success criteria. Preclinical milestones may include in vivo proof of concept in disease animal models, lead candidate identification, and completion of IND-enabling toxicology studies. Clinical milestones may, for example, include successful enrollment of the first patient in or completion of Phase 1, 2 and 3 clinical trials, and commercial milestones are often tiered based on net or aggregate sale amounts. The Company cannot guarantee the achievement of these milestones due to risks associated with preclinical and clinical activities required for development of nucleic acid medicine-based therapeutics and vaccines.
The following table presents changes during the six months ended June 30, 2025 in the balances of contract assets and liabilities as compared to what was disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.
(in thousands) |
|
December 31, 2024 |
|
|
Additions |
|
|
Deductions |
|
|
June 30, 2025 |
|
||||
Contract Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Accounts receivable |
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|||
Contract Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Deferred revenue |
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|||
The following table summarizes the Company’s revenues for the periods indicated.
|
|
For the Three Months |
|
|
For the Six Months |
|
||||||||||
(in thousands) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Collaboration Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
CSL Seqirus |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Other collaboration revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total collaboration revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Grant revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
BARDA |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Total grant revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
The following paragraphs provide information regarding the nature and purpose of the Company’s most significant collaboration and grant arrangements.
6
CSL Seqirus
On November 1, 2022, the Company entered into a Collaboration and License Agreement (as amended, the “CSL Collaboration Agreement”) with Seqirus, Inc., a part of CSL Limited (“CSL Seqirus”), for the global exclusive rights to research, develop, manufacture, and commercialize vaccines. Under the terms of the CSL Collaboration Agreement, the Company provides CSL Seqirus with an exclusive global license to its mRNA technology (including STARR®) and LUNAR® lipid-mediated delivery, along with mRNA drug substance and drug product manufacturing processes. CSL Seqirus will lead the development and commercialization of vaccines under the collaboration. The collaboration plans to advance vaccines against SARS-CoV-2 (COVID-19), influenza, pandemic preparedness as well as three other infectious diseases. In September 2024, our COVID-19 vaccine KOSTAIVE® became the world’s first approved and commercially available self-amplifying RNA (sa-mRNA) vaccine.
The Company received a $
In evaluating the CSL Collaboration Agreement in accordance with ASC 606, the Company concluded that CSL Seqirus is a customer. The Company identified all promised goods/services within the CSL Collaboration Agreement, and when combining certain promised goods/services, the Company concluded that there are five distinct performance obligations. The nature of the performance obligations consists of the delivery of the vaccine license, research and development services for COVID-19 and non-COVID-19 vaccines and regulatory activities for COVID-19 vaccines. For each performance obligation, the Company estimated the standalone selling price based on 1) in the case of the license, the fair value using costs to recreate plus margin method and 2) in the case of research and development services and regulatory activities, cost plus margin for estimated full-time equivalent (“FTE”) costs, direct costs including laboratory supplies, contractors, and other out-of-pocket expenses for research and development services and regulatory activities.
As of June 30, 2025, the transaction price consisted of upfront consideration received and milestones achieved. Additional variable consideration was not included in the transaction price as of June 30, 2025, because the Company could not conclude that it is probable that including the variable consideration will not result in a significant revenue reversal.
The Company allocated the transaction price to the performance obligations in proportion to their standalone selling price. The vaccine license was recognized at the point in time it was transferred in 2022. The research and development and regulatory activities performance obligations are recognized over a period of time based on the percentage of services rendered using the input method, meaning actual costs incurred divided by total costs budgeted to satisfy the performance obligation. Any consideration related to sales-based royalties will be recognized when the amounts are probable of non-reversal, provided that the reported sales are reliably measurable and the Company has no remaining promised goods/services, as they are constrained and therefore have also been excluded from the transaction price. The revenue recognized in the second quarter of 2025 relates to the license delivered, milestones achieved and services performed through June 30, 2025.
Total deferred revenue as of June 30, 2025 and December 31, 2024 for the CSL Collaboration Agreement was $
During 2023, the Company entered into an amendment to the CSL Collaboration Agreement, pursuant to which the Company agreed to sponsor and conduct a Phase 1 clinical study in the influenza field. As part of the amendment, the Company received $
During the fourth quarter of 2023, the Company received an advance payment of $
7
In March 2024, the Company entered into an amendment to the CSL Collaboration Agreement, pursuant to which the parties agreed to, among other things, adjust (i) the development plans for certain product candidates, (ii) various development milestones related to such product candidates, (iii) provisions of the CSL Collaboration Agreement related to specific royalty payments, (iii) provisions of the CSL Collaboration Agreement related to distributors, and (iv) proprietary payment calculations related to the foregoing.
BARDA Grant
In August 2022, the Company entered into a cost reimbursement contract (the “BARDA Contract”) with the Biomedical Advanced Research and Development Authority ("BARDA"), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) for an award of up to $
The Company determined that the BARDA Contract is not in the scope of ASC 808 or ASC 606. Applying International Accounting Standards No. 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, the Company recognizes grant revenue from the reimbursement of direct out-of-pocket expenses, overhead allocations and fringe benefits for research costs associated with the grant. The costs associated with these reimbursements are reflected as a component of research and development expense in the Company’s condensed consolidated statements of operations and comprehensive loss.
As of June 30, 2025, the remaining available funding net of revenue earned was $
Note 3. Fair Value Measurements
The Company establishes the fair value of its assets and liabilities using the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company established a fair value hierarchy based on the inputs used to measure fair value.
The three levels of the fair value hierarchy are as follows:
Level 1: Quoted prices in active markets for identical assets or liabilities.
Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.
Level 3: Unobservable inputs in which little or no market data exists and are therefore determined using estimates and assumptions developed by the Company, which reflect those that a market participant would use.
The carrying value of cash, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values due to their relatively short maturities.
As of June 30, 2025 and December 31, 2024, all assets measured at fair value on a recurring basis consisted of cash equivalents and money market funds, which were classified within Level 1 of the fair value hierarchy. The fair value of these financial instruments was measured based on quoted prices.
Note 4. Other Balance Sheet Details
Property and equipment, net balances consisted of the following:
(in thousands) |
|
June 30, 2025 |
|
|
December 31, 2024 |
|
||
Research equipment |
|
$ |
|
|
$ |
|
||
Computers and software |
|
|
|
|
|
|
||
Office equipment and furniture |
|
|
|
|
|
|
||
Leasehold improvements |
|
|
|
|
|
|
||
Total |
|
|
|
|
|
|
||
Less accumulated depreciation and amortization |
|
|
( |
) |
|
|
( |
) |
Property and equipment, net |
|
$ |
|
|
$ |
|
||
Depreciation and amortization expense was $
8
Accrued liabilities consisted of the following:
(in thousands) |
|
June 30, 2025 |
|
|
December 31, 2024 |
|
||
Accrued compensation |
|
$ |
|
|
$ |
|
||
Cystic Fibrosis Foundation liability |
|
|
|
|
|
|
||
Current portion of |
|
|
|
|
|
|
||
Clinical trial accruals |
|
|
|
|
|
|
||
Vinbiocare contractual liabilities |
|
|
|
|
|
|
||
Legal accrual |
|
|
|
|
|
|
||
Other accrued research and development expenses |
|
|
|
|
|
|
||
Total |
|
$ |
|
|
$ |
|
||
The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same such amounts shown in the unaudited condensed consolidated statement of cash flows as of June 30, 2025 and 2024:
(in thousands) |
|
June 30, 2025 |
|
|
June 30, 2024 |
|
||
Cash and cash equivalents |
|
$ |
|
|
$ |
|
||
Restricted cash |
|
|
|
|
|
|
||
Non-current restricted cash |
|
|
|
|
|
|
||
Total cash, cash equivalents and restricted cash |
|
$ |
|
|
$ |
|
||
Restricted cash includes collateral pledged and held in the Company’s securities accounts pursuant to a security agreement with Wells Fargo Bank, National Association (“Wells Fargo”) (Note 5). As of June 30, 2025, such collateral amounted to $
Restricted cash also includes cash required to be set aside as security for lease payments and to maintain a letter of credit for the benefit of the landlord of the Company’s offices. As of June 30, 2025 and 2024, the Company had restricted cash of $
Note 5. Debt
Wells Fargo Credit Agreement
The Company’s wholly-owned subsidiary, Arcturus Therapeutics, Inc. (“Arcturus Therapeutics”) entered into a credit agreement with Wells Fargo Bank on April 21, 2023, and amended on June 26, 2024, whereby Wells Fargo will make a $
Borrowings under the agreement will bear interest at a rate of
The term of the agreement was originally
9
whereby the term of the Note was extended by
Note 6. Stockholders’ Equity
Net Loss per Share
Potentially dilutive securities that were not included in the calculation of diluted net loss per share as they were anti-dilutive totaled
Sales Agreement
On December 23, 2022, the Company entered into a Controlled Equity Offering℠ Sales Agreement, which was amended on August 7, 2023 (as amended, the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”),Wells Fargo Securities, LLC (“Wells Fargo Securities”), and William Blair & Company, L.L.C. (“William Blair”) relating to shares of the Company's common stock. In accordance with the terms of the Sales Agreement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $
Note 7. Share-Based Compensation Expense
In June 2024 at the Company’s 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"), the stockholders of the Company approved an amendment to the Company’s 2019 Omnibus Equity Incentive Plan (as amended, the “2019 Plan”) which, among other things, increased the aggregate number of shares authorized for use in making awards to eligible persons under the 2019 Plan by
In October 2021, the Company adopted the 2021 Inducement Equity Incentive Plan which covers the award of up to
Share-Based Compensation
Share-based compensation expense included in the Company’s condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2025 and 2024 was as follows:
|
|
For the Three Months |
|
|
|
For the Six Months |
|
||||||||||
(in thousands) |
|
2025 |
|
|
2024 |
|
|
|
2025 |
|
|
2024 |
|
||||
Research and development |
|
$ |
|
|
$ |
|
|
|
$ |
|
|
$ |
|
||||
General and administrative |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total |
|
$ |
|
|
$ |
|
|
|
$ |
|
|
$ |
|
||||
Note 8. Income Taxes
The Company is subject to taxation in the United States and various states. The Company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. The primary difference between the effective tax rate and the federal statutory rate is due to federal and state income tax expense offset by valuation allowance on the Company's deferred tax assets.
The Company recorded negligible income tax expense for the three and six months ended June 30, 2025. For the same periods in 2024, the Company recognized an income tax benefit of $
Recent Tax Legislation
10
On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law, which enacts significant changes to U.S. tax and related laws. Some of the provisions of the new tax law affecting corporations include but are not limited to current deduction of domestic research expenses, increasing the limit of the deduction of interest expense deduction to thirty percent of EBITDA, and one hundred percent bonus depreciation on eligible property acquired after January 19, 2025. The Company is currently evaluating the impact the new tax law will have on its financial condition and results of operations. Preliminarily, the Company does anticipate a change to its effective income tax rate, its net deferred federal income tax Liability and a decrease in current taxes payable; however a reasonable estimate is not available at this time. The impact of the tax law changes from the OBBBA will be included in the Company’s financial statements beginning in the three-months ending September 30, 2025.
Note 9. Commitments and Contingencies
Cystic Fibrosis Foundation Agreement
On September 25, 2023, the Company amended its Development Program Letter Agreement, dated May 16, 2017 and as amended July 13, 2018 and August 1, 2019, with the Cystic Fibrosis Foundation (“CFF”). Pursuant to the amendment, (i) CFF increased the amount it will award to advance LUNAR-CF to $
Leases
In October 2017, the Company entered into a non-cancellable operating lease agreement for office space adjacent to its previously occupied headquarters. The commencement of the lease began in March 2018 and the lease extends for approximately
The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $
In February 2020, the Company entered into a second non-cancellable operating lease agreement for office space near its current headquarters. The lease extended for
In September 2021, the Company entered into a third non-cancellable lease agreement for office, research and development, engineering and laboratory space near its current headquarters, and such lease term commenced during the second quarter of 2022. The initial term of this lease extends
Operating lease right-of-use asset and liability on the consolidated balance sheets represent the present value of remaining lease payments over the remaining lease terms. The Company does not allocate lease payments to non-lease components; therefore, payments for common-area-maintenance and administrative services are not included in the operating lease right-of-use asset and liability. The Company uses its incremental borrowing rate to calculate the present value of the lease payments, as the implicit rate in the lease is not readily determinable.
11
As of June 30, 2025, the remaining payments of the operating lease liability were as follows:
(in thousands) |
|
Remaining Lease Payments |
|
|
2025 (remainder of year) |
|
$ |
|
|
2026 |
|
|
|
|
2027 |
|
|
|
|
2028 |
|
|
|
|
2029 |
|
|
|
|
Thereafter |
|
|
|
|
Total remaining lease payments |
|
|
|
|
Less: imputed interest |
|
|
( |
) |
Total operating lease liabilities |
|
$ |
|
|
Weighted-average remaining lease term |
|
|
|
|
Weighted-average discount rate |
|
|
% |
|
Operating lease costs consist of the fixed lease payments included in operating lease liability and are recorded on a straight-line basis over the lease terms. Operating lease costs were $
Note 10. Segment Information
The Company operates in
The following table presents information about reported segment revenues, segment loss and income, and significant segment expenses:
|
|
For the Three Months |
|
|
For the Six Months Ended June 30, |
|
||||||||||||
(in thousands) |
|
2025 |
|
|
|
2024 |
|
|
2025 |
|
|
|
2024 |
|
||||
Revenues |
|
$ |
|
|
|
$ |
|
|
$ |
|
|
|
$ |
|
||||
Less: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
LUNAR-COVID |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
LUNAR-OTC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
BARDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
LUNAR-CF, net |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Early-stage programs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Discovery technologies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Payroll and benefits |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Facilities and equipment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total research and development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
General and administrative |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other (1) |
|
|
( |
) |
|
|
|
( |
) |
|
|
( |
) |
|
|
|
( |
) |
Net loss |
|
$ |
( |
) |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
|
$ |
( |
) |
(1)
Note 11. Related Party Transactions
Equity-method Investment - ARCALIS, Inc.
Investments for which the Company exercises significant influence, but does not have control are accounted for under the equity method. Equity-method investment activity is related to the Company's joint venture in ARCALIS, Inc. with Axcelead, Inc. The Company’s share of the investees’ results is presented as either income or loss from equity-method investees in the accompanying
12
consolidated statements of operations and comprehensive loss. As of June 30, 2025, the carrying value of the equity-method investment in ARCALIS remained at
13
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following is a discussion of the financial condition and results of operations of Arcturus Therapeutics Holdings Inc. for the three- and six-month periods ended June 30, 2025. Unless otherwise specified herein, references to the “Company,” “Arcturus,” “we,” “our” and “us” mean Arcturus Therapeutics Holdings Inc. and its consolidated subsidiaries. You should read the following discussion and analysis together with the interim condensed consolidated financial statements and related notes included elsewhere herein. For additional information relating to our management’s discussion and analysis of financial conditions and results of operations, please see our Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Annual Report”), which was filed with the U.S. Securities and Exchange Commission (the “Commission”) on March 6, 2025. Unless otherwise defined herein, capitalized words and expressions used herein shall have the same meanings ascribed to them in the 2024 Annual Report.
This report includes forward-looking statements which, although based on assumptions that we consider reasonable, are subject to risks and uncertainties which could cause actual events or conditions to differ materially from those currently anticipated and expressed or implied by such forward-looking statements. This report also includes certain statements based solely on information, reports and studies provided by or conducted by Seqirus, Inc. and Meiji Holdings Co., Ltd or their respective affiliates.
You should read this report and the documents that we reference in this report and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially different from what we expect. You should also review the factors and risks we describe in the reports we will file or submit from time to time with the Commission after the date of this report.
Overview
We are a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines. We developed the world’s first approved self-amplifying messenger RNA (sa-mRNA) vaccine, KOSTAIVE® (“KOSTAIVE”). KOSTAIVE achieved approval in Japan in 2023 as a vaccine against COVID-19. Sales of KOSTAIVE began in Japan in October 2024, marking our transition to a commercial stage company.
We have several key platform technologies that we leverage to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and for rare genetic disorders with significant unmet medical needs. Current mRNA medicines have two critical components: the messenger RNA (“mRNA”) constructs and the lipid nanoparticles (“LNP”) which help deliver the mRNA to disease-relevant target tissues. We have extensive expertise in the design and optimization of mRNA constructs, including with respect to a type of mRNA technology known as self-amplifying mRNA (sa-mRNA). Our proprietary self-amplifying mRNA technology platform, or STARR® (“STARR”), has been demonstrated to induce a longer-lasting and broader humoral immune response at lower dose levels than conventional mRNA-based vaccines. Our proprietary LNP delivery system, LUNAR® (“LUNAR”), is intended to address the major hurdle in RNA drug development, namely the effective and safe delivery of RNA therapeutics to disease-relevant target tissues. LUNAR may enable multiple nucleic acid medicines. Finally, we have significant expertise and valuable know-how in the development and scalability of complex and robust manufacturing processes required to deliver the next generation of nucleic acid medicines.
Our internal pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), both rare diseases. In our vaccine program, we have partnered with Seqirus, Inc. (“CSL Seqirus”), a part of CSL Limited and one of the world’s leading influenza vaccine providers, on the development and commercialization of mRNA vaccines for COVID-19, influenza, and three other infectious diseases.
Business Updates
Vaccine Collaboration with CSL Seqirus
In November 2022, we entered into a Collaboration and License Agreement (as amended, the “CSL Collaboration Agreement”) with Seqirus, Inc. (“CSL Seqirus”), a part of CSL Limited, and one of the world’s leading influenza vaccine providers, for global exclusive rights to research, develop, manufacture and commercialize self-amplifying mRNA vaccines against COVID-19, influenza and three other infectious diseases and global non-exclusive rights to pandemic pathogens.
In November 2023, KOSTAIVE received marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for use as a primary immunization and booster in Japan for adults 18 years and older. Commercial sales of KOSTAIVE began in Japan in October 2024 by Meiji Seika Pharma (“Meiji”), CSL Seqirus’ exclusive partner in Japan.
KOSTAIVE® is the brand name approved in Japan and Europe for ARCT-154, which is the version of the sa-mRNA COVID vaccine encoding the ancestral strain of SARS-CoV-2, and for updated variant-specific versions of this vaccine. We may use KOSTAIVE or the specific internally generated name, such as ARCT-154, to identify the vaccine.
14
In January 2025, CSL Seqirus’ partner Meiji announced that it received approval for a partial amendment to the manufacturing and marketing approval of KOSTAIVE to include manufacturing sites in Japan. With this approval, Meiji and ARCALIS, Inc., Arcturus’ manufacturing joint venture in Japan, have been added as manufacturing sites. As a result, KOSTAIVE, with active pharmaceutical ingredients manufactured at such sites, may be shipped for commercial use in Japan.
Approval of KOSTAIVE (ARCT-154) in Europe
In February 2025, the European Commission granted marketing authorization for KOSTAIVE (ARCT-154) for individuals 18 years of age and older. The European Commission approval follows a positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on December 12, 2024. The centralized marketing authorization of KOSTAIVE provided by the EC is valid in all 27 European Union (EU) member states and 3 additional European Economic Area (EEA) countries summarized here: Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, The Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden. The approval of KOSTAIVE in Europe, as well as the approval in Japan, are significant milestones, which further validate our LUNAR and STARR platforms, as well as sa-mRNA more generally as a meaningful modality.
Marketing Authorization Application filing of KOSTAIVE in United Kingdom
In June 2025, CSL Seqirus submitted a marketing authorization application (“MAA”) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for KOSTAIVE.
Clinical Studies of KOSTAIVE (COVID-19 vaccine)
In connection with our collaboration with CSL Seqirus, we continue to collect data from various ongoing studies. See the 2024 Annual Report for a description of studies.
Recent KOSTAIVE Publications
In April 2025, we published a comprehensive analysis of safety data for KOSTAIVE®, with a 12-month follow-up from the pivotal clinical study in Vietnam (NCT05012943), which had 17,582 participants who received at least one dose of the study vaccine (https://doi.org/10.1080/14760584.2025.2487542). The study confirmed the favorable reactogenicity profile of the vaccine.
Acceptable tolerability of KOSTAIVE (ARCT-154) was also observed in older participants and individuals who are at risk of severe consequences of COVID-19 due to underlying medical conditions. Long-term follow-up has not revealed any safety concerns, with no reports of myocarditis or pericarditis. No serious consequences occurred in several pregnancies reported after vaccination. Long-term data from this large trial suggest that the KOSTAIVE is safe and well-tolerated.
In April 2025, our Japanese partner, Meiji, published an analysis characterizing the distribution and clearance of KOSTAIVE (ARCT-154) encoded spike protein and non-structural proteins nsP1, nsP2, nsP3 and nsP4 in the lymph nodes and injection-site muscle in mice following a single vaccination. The study showed the encoded spike protein reached its highest level approximately three days after vaccination and quickly disappeared from the injection site muscle. The spike protein levels also peaked at an early time point in the lymph nodes, it remained detectable 28 days after the vaccination and disappeared by 44 days after the vaccination. Expression of nsP1, nsP2 and nsP4 was observed in the injected muscle and/or the lymph nodes for up to 15 days post-vaccination. The data indicates that the extended expression of spike proteins in lymph nodes may be responsible for the induction of higher and prolonged levels of neutralizing antibodies. The study also confirmed that the self-replication is limited over time.
In July 2025, we published the manuscript ‘Immunogenicity of ARCT-154, a self-amplifying mRNA COVID-19 vaccine, in different booster settings’ (https://doi.org/10.1016/j.jvacx.2025.100693) where we summarized extensive clinical data and concluded that KOSTAIVE (ARCT-154), administered as a homologous or heterologous booster after previous COVID-19 vaccination or natural exposure, provides robust, broad and durable immune responses against SARS-CoV-2 viruses.
In July 2025, a researcher from Tokyo University, Japan, published the manuscript ‘A second-generation, self-amplifying COVID-19 Vaccine: World’s first approval and distribution in the Japanese market with vaccine hesitancy’ (https://doi.org/10.1080/21645515.2025.2530291). The manuscript positions KOSTAIVE as a second-generation mRNA vaccine, differentiating it based on effective dose, durability, and breadth of immune response, and summarizes experience from the first year of routine use of the vaccine in Japan.
In August 2025, the manuscript ‘Immunogenicity and Safety of Self-Amplifying mRNA COVID-19 Vaccine (ARCT-2303), With or Without Co-Administration of Seasonal Inactivated Influenza Vaccine in Adults: a Phase 3, Randomised, Controlled, Observer-blind, Multicentre Study’ was accepted by eClinicalMedicine. The manuscript includes the results of the recent pivotal Phase 3 clinical study and concludes that KOSTAIVE (ARCT-2303; XBB.1.5 strain) induces a robust immune response against the vaccine variant of SARS-CoV-2 and can be co-administered with licensed influenza vaccines in adults with no impact on the safety or immunogenicity of either vaccine.
15
Seasonal Influenza Program Updates
Under our collaboration with CSL Seqirus, we conducted a Phase 1 study of ARCT-2138, a sa-mRNA seasonal influenza vaccine candidate encoding haemagglutinin (HA) and neuraminidase (NA) of four seasonal influenza strains as recommended by the World Health Organization (WHO). The study objectives were to evaluate the safety and tolerability and to describe the immune response of different dose levels of the vaccine in 100 young adults (18-49 years of age) and 35 older adults (≥65 years of age).
All tested dose levels of ARCT-2138 were immunogenic as measured by hemagglutinin-inhibition assay in both age groups, demonstrating a modest dose-response (≤2.1-fold) within the range of the tested doses (2-20 μg). ARCT-2138 also induced NA-specific antibody response against all four influenza strains in all tested dose levels in both age groups. In both age categories, HA- and NA-specific antibodies demonstrated a good persistence profile within 6 months post-vaccination.
In younger and older adults, the higher dose levels (12 μg and 20 μg) of ARCT-2138 tended to be more reactogenic than the comparator licensed influenza vaccines. Most solicited adverse events were reported within 24 hours after vaccination and resolved within 2-4 days. The frequencies of unsolicited adverse events and medically attended adverse events appeared to be comparable between ARCT-2138 and comparator vaccines. No major safety concerns were raised from the study results.
Overall, the study showed the potential of a self-amplifying mRNA vaccine, encoding eight antigens, to induce an immune response in both young and older adults with a dose as low as 2 μg, and was tolerable across a dose range of 2 to 20 μg.
Pandemic Avian Influenza Program (H5N1 Influenza) Updates
Our LUNAR-H5N1 program, which is part of the CSL Collaboration Agreement, continues to progress under the award from BARDA that we obtained in 2022 to advance through Phase 1 a vaccine to protect against disease caused by H5N1 highly-pathogenic avian influenza.
The Phase 1 study of ARCT-2304, an sa-mRNA vaccine candidate, also known as LUNAR-H5N1, initiated dosing in December 2024 and continues to advance. We recently completed the recruitment of 212 adults (132 participants 18-59 years old; 80 participants 60+ years old) for the randomized placebo-controlled Phase 1 trial (NCT06602531), which is being conducted at multiple sites in the U.S. The primary objective of this initial clinical trial is to evaluate the safety and immune responses of three different dose levels and two different vaccination schedules of the ARCT-2304 vaccine. Immune responses are measured by hemagglutination inhibition (HAI), virus microneutralization (MN) and neuraminidase enzyme-linked lectin assays (ELLA). The recruitment in this study was completed in April 2025.
In April 2025, the U.S. Food and Drug Administration (“FDA”) granted Fast Track Designation for ARCT-2304. This designation recognizes the potential of ARCT-2304 as an innovative approach to address unmet medical needs for the prevention of disease caused by pandemic influenza A virus H5N1, a significant global health risk. Fast Track Designation from the FDA is granted to vaccines intended to prevent serious conditions caused by infectious diseases. The designation is designed to expedite the development and review process, providing several benefits, including enhanced communication with the FDA, eligibility for priority review, and the possibility of a rolling review.
Key Updates on Arcturus-Owned mRNA Therapeutic Development Candidates
16
The U.S. IND including the ongoing Phase 2 protocol was allowed to proceed in August 2024. The Phase 2 study is an open-label, multiple ascending dose study to assess safety and efficacy of ARCT-032 in CF adults who do not benefit from current CFTR modulators, including those with Class I null mutations. We initiated dosing in the study in the U.S. in December 2024 and enrollment is ongoing. Each participant in the Phase 2 CF study (NCT06747858) receives daily inhaled treatments of ARCT-032 for 28 days, with dose escalation expected to occur following safety reviews of the data.
On June 30, 2025, we announced positive multiple dosing data of ARCT-810 from two Phase 2 studies: (i) a completed placebo-controlled study in Europe that randomized eight participants to ARCT-810 0.3 mg/kg or placebo; and (ii) an open-label multiple ascending dose study in the U.S., with interim data from the initial three completed participants. Both studies evaluate safety and pharmacodynamics in adult and adolescent patients requiring clinical management for OTC-deficiency. We continue to enroll participants in the U.S. study. Each participant in the U.S. study is expected to receive five intravenous infusions administered over two months.
A Linear Mixed-Effects Model (LMM) was applied as an exploratory analysis to the Phase 2 glutamine and ureagenesis data. LMM is suitable for small-N analyses, i.e. rare disease trial datasets. In the Phase 2 randomized European study, glutamine levels in patients who received multiple doses of ARCT-810 significantly (p-value = 0.016; LMM) decreased during the dosing period. In the Phase 2 open-label U.S. study, all three participants had a sustained and significant (p-value = 0.004; LMM) decrease in glutamine from baseline reaching normal levels after the first three doses. In the combined analysis of both Phase 2 studies, significantly (p-value = 0.0055; LMM) decreased glutamine levels were observed. The ongoing U.S. Phase 2 open-label study uses a modified and improved 15N-ureagenesis assay (Allegri et al., 2025). The assay measures relative ureagenesis function (RUF) against a normal range established from healthy controls. The assay is not impacted by ammonia scavengers, has low intraindividual variability, and can distinguish between symptomatic and asymptomatic OTC deficient patients. In the first three participants in the ongoing Phase 2 open-label study, RUF statistically (p-value = 0.026, LMM) increased at all post treatment evaluations from a baseline of 29.0% (SD; 9.1%) to 43.7% (SD; 21.7%) at 28 days post-fifth dose. These results suggest a progressive increase of functional OTC enzyme in the liver with continued administrations. Two of the three participants achieved RUF > 50% indicating a clinically meaningful improvement in urea cycle flux.
ARCT-810 was generally safe and well tolerated in single dose Phase 1/1b and multi-dose Phase 2 studies, comprising 40 participants to date, including 20 OTC deficient participants. The early studies enabled us to improve the tolerability of the infusion regime without using corticosteroid pre-treatment. To date, no serious infusion-related reactions (“IRRs”) have been observed using the improved 3-hour IV regimen (N = 8; up to 6 infusions) in the Phase 2 protocols.
Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Report and our audited financial statements and related notes for the year ended December 31, 2024. Our historical results of operations and the year-to-year comparisons of our results of operations that follow are not necessarily indicative of future results.
Revenue
We enter into arrangements with pharmaceutical and biotechnology partners and government agencies that may contain upfront payments, license fees for research and development arrangements, research and development funding, milestone payments, option exercise and exclusivity fees and royalties on future sales. The following table summarizes our total revenues for the periods indicated:
|
|
Three Months Ended June 30, |
|
|
Change 2025 vs 2024 |
|
||||||||||
(in thousands) |
|
2025 |
|
|
2024 |
|
|
Change |
|
|
% |
|
||||
Revenue |
|
$ |
28,301 |
|
|
$ |
49,859 |
|
|
$ |
(21,558 |
) |
|
|
-43 |
% |
17
Revenue decreased by $21.6 million during the three months ended June 30, 2025, as compared to the three months ended June 30, 2024. The decrease was due to reduced revenue related to the CSL collaboration, caused by less revenue from supply agreements and less amortization as KOSTAIVE transitions from a development program to the commercial phase.
|
|
Six Months Ended June 30, |
|
|
Change 2025 vs 2024 |
|
||||||||||
(in thousands) |
|
2025 |
|
|
2024 |
|
|
$ change |
|
|
% change |
|
||||
Revenue |
|
$ |
57,683 |
|
|
$ |
87,871 |
|
|
$ |
(30,188 |
) |
|
|
-34 |
% |
Revenue decreased by $30.2 million during the six months ended June 30, 2025, as compared to the six months ended June 30, 2024. The decrease was primarily attributable to a $28.4 million reduction in revenue related to the CSL collaboration during the current period, caused by less revenue from supply agreements and less amortization as KOSTAIVE transitions from a development program to the commercial phase.
Operating Expense
Our operating expenses consist of research and development and general and administrative expenses.
|
|
Three Months Ended June 30, |
|
|
Change 2025 vs 2024 |
|
|
Six Months Ended June 30, |
|
|
2024 to 2025 |
|
||||||||||||||||||||
(in thousands) |
|
2025 |
|
|
2024 |
|
|
$ change |
|
|
% change |
|
|
2025 |
|
|
2024 |
|
|
$ change |
|
|
% change |
|
||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Research and development, net |
|
$ |
29,579 |
|
|
$ |
58,669 |
|
|
$ |
(29,090 |
) |
|
|
-50 |
% |
|
$ |
64,471 |
|
|
$ |
112,242 |
|
|
$ |
(47,771 |
) |
|
|
-43 |
% |
General and administrative |
|
|
10,338 |
|
|
|
12,316 |
|
|
|
(1,978 |
) |
|
|
-16 |
% |
|
|
21,654 |
|
|
|
27,167 |
|
|
|
(5,513 |
) |
|
|
-20 |
% |
Total |
|
$ |
39,917 |
|
|
$ |
70,985 |
|
|
$ |
(31,068 |
) |
|
|
-44 |
% |
|
$ |
86,125 |
|
|
$ |
139,409 |
|
|
$ |
(53,284 |
) |
|
|
-38 |
% |
Research and Development Expenses, net
The following table presents our total research and development expenses by category:
|
|
Three Months Ended June 30, |
|
|
Change 2025 vs 2024 |
|
|
Six Months Ended June 30, |
|
|
2024 to 2025 |
|
||||||||||||||||||||
(in thousands) |
|
2025 |
|
|
2024 |
|
|
$ change |
|
|
% change |
|
|
2025 |
|
|
2024 |
|
|
$ change |
|
|
% change |
|
||||||||
LUNAR-COVID |
|
$ |
3,831 |
|
|
$ |
22,327 |
|
|
$ |
(18,496 |
) |
|
|
-83 |
% |
|
$ |
9,640 |
|
|
$ |
43,057 |
|
|
$ |
(33,417 |
) |
|
|
-78 |
% |
LUNAR-OTC |
|
|
2,901 |
|
|
|
4,927 |
|
|
|
(2,026 |
) |
|
|
-41 |
% |
|
|
4,477 |
|
|
|
6,310 |
|
|
|
(1,833 |
) |
|
|
-29 |
% |
BARDA |
|
|
2,459 |
|
|
|
2,367 |
|
|
|
92 |
|
|
|
4 |
% |
|
|
4,941 |
|
|
|
5,602 |
|
|
|
(661 |
) |
|
|
-12 |
% |
LUNAR-CF, net |
|
|
4,629 |
|
|
|
5,610 |
|
|
|
(981 |
) |
|
|
-17 |
% |
|
|
11,777 |
|
|
|
6,805 |
|
|
|
4,972 |
|
|
|
73 |
% |
Early-stage programs |
|
|
167 |
|
|
|
6,298 |
|
|
|
(6,131 |
) |
|
|
-97 |
% |
|
|
164 |
|
|
|
12,466 |
|
|
|
(12,302 |
) |
|
|
-99 |
% |
Discovery technologies |
|
|
2,439 |
|
|
|
863 |
|
|
|
1,576 |
|
|
* |
|
|
|
4,627 |
|
|
|
2,053 |
|
|
|
2,574 |
|
|
* |
|
||
Payroll and benefits |
|
|
10,611 |
|
|
|
13,998 |
|
|
|
(3,387 |
) |
|
|
-24 |
% |
|
|
23,654 |
|
|
|
29,515 |
|
|
|
(5,861 |
) |
|
|
-20 |
% |
Facilities and equipment |
|
|
2,542 |
|
|
|
2,279 |
|
|
|
263 |
|
|
|
12 |
% |
|
|
5,191 |
|
|
|
6,434 |
|
|
|
(1,243 |
) |
|
|
-19 |
% |
Total research and development expenses, net |
|
$ |
29,579 |
|
|
$ |
58,669 |
|
|
$ |
(29,090 |
) |
|
|
-50 |
% |
|
$ |
64,471 |
|
|
$ |
112,242 |
|
|
$ |
(47,771 |
) |
|
|
-43 |
% |
* Greater than 100%
Our research and development expenses consist primarily of external manufacturing costs, in-vivo research studies and clinical trials performed by contract research organizations, clinical and regulatory consultants, personnel related expenses, facility related expenses and laboratory supplies related to conducting research and development activities.
Research and development expenses were $29.6 million for the three months ended June 30, 2025, compared with $58.7 million for the three months ended June 30, 2024. The decrease was primarily driven by lower manufacturing costs related to the LUNAR-COVID, LUNAR-FLU, and LUNAR-CF programs, as well as reduced clinical trial expenses associated with the LUNAR-COVID and LUNAR-OTC programs. Additional decreases were attributable to lower payroll and benefits costs. These reductions were partially offset by increased clinical costs related to the LUNAR-CF program as we began Phase II clinical trials in fiscal year 2025.
Research and development expenses were $64.5 million for the six months ended June 30, 2025, compared with $112.2 million for the six months ended June 30, 2024. The decrease was primarily driven by lower manufacturing and clinical costs related to the LUNAR-COVID program, reflecting the program’s transition from a development program to the commercial phase. Additional
18
decreases were attributable to lower payroll and benefits expenses, as well as reduced facilities and equipment costs as we downsized from three to two facilities. These reductions were partially offset by increased clinical costs related to the LUNAR-CF program.
Early-stage programs represent programs that are in the pre-clinical or Phase 1 clinical stage and may be partnered or unpartnered, and primarily includes the LUNAR-FLU program which is partnered with CSL Seqirus. Discovery technologies represent our efforts to expand our product pipeline and are primarily related to pre-partnered studies and new capabilities assessment. A few of our programs are part of our collaborative relationships. The related expenses may be partially offset with funds that have been reimbursed or awarded to the Company and consist of external manufacturing costs, lab supplies, equipment, and consulting and professional fees. Expenses for both early-stage programs and discovery technologies are expected to decrease as we shift our focus to later-stage programs.
Payroll and benefits primarily consists of employee salaries and benefits, share-based compensation and consultant costs. We expect that payroll and benefits costs will not increase over the next twelve months due to reduced share-based compensation expense.
Facilities and equipment expenses include rent, common area maintenance (“CAM”) costs, depreciation, shipping costs and various other costs related to the operation of our two office and laboratory locations. These costs decreased during the first six months of 2025 as compared to the first six months of 2024, as we downsized from three to two facilities. Facilities and equipment expenses are not expected to increase during the next twelve months.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and related benefits for our executive, administrative and accounting functions and professional service fees for legal and accounting services as well as other general and administrative expenses.
General and administrative expenses were $10.3 million for the three months ended June 30, 2025, compared with $12.3 million for the three months ended June 30, 2024. General and administrative expenses were $21.7 million for the six months ended June 30, 2025, compared with $27.2 million for the six months ended June 30, 2024. The decreases in both periods were primarily due to reduced share-based compensation expense as well as reduced payroll and benefits.
Finance income, net
|
|
Three Months Ended June 30, |
|
|
Change 2025 vs 2024 |
|
|
Six Months Ended June 30, |
|
|
Change 2025 vs 2024 |
|
||||||||||||||||||||
(in thousands) |
|
2025 |
|
|
2024 |
|
|
$ change |
|
|
% change |
|
|
2025 |
|
|
2024 |
|
|
$ change |
|
|
% change |
|
||||||||
Interest income |
|
$ |
2,567 |
|
|
$ |
4,148 |
|
|
$ |
(1,581 |
) |
|
|
-38 |
% |
|
$ |
5,339 |
|
|
$ |
8,164 |
|
|
$ |
(2,825 |
) |
|
|
-35 |
% |
Interest income is generated on the Company’s cash and cash equivalents. The decrease in interest income for the three and six months ended June 30, 2025, compared to the same periods in 2024, was primarily due to lower interest rates and a reduced cash balance.
Off-balance sheet arrangements
Through June 30, 2025, we have not entered into and did not have any relationships with unconsolidated entities or financial collaborations, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.
Liquidity and Capital Resources
From the Company’s inception through the quarter ended June 30, 2025, the Company has funded its operations principally with the proceeds from revenues earned through collaboration agreements and government contracts, the sale of capital stock and long-term debt. Through the second quarter of 2025, we have achieved a total of approximately $509.7 million in upfront payments and milestones from CSL Seqirus, including milestones of $20.0 million achieved in the current quarter. We expect to receive future payments from CSL Seqirus primarily by meeting future milestones related to the CSL Collaboration Agreement. As of June 30, 2025, the Company’s balance of cash and cash equivalents, including restricted cash, was $253.4 million.
CSL Seqirus, Inc. Collaboration and License Agreement
In 2022, we entered into the CSL Collaboration Agreement with CSL Seqirus, a part of CSL Limited, one of the world’s leading influenza vaccine providers, for the global exclusive rights to research, develop, manufacture and commercialize mRNA vaccines.
CSL Seqirus received exclusive global rights to our technology for vaccines against SARS-CoV-2 (COVID-19), influenza and three other infectious diseases with non-exclusive rights to pandemic pathogens. We received an up-front payment of $200.0 million during the fourth quarter of 2022. We will be eligible to receive development milestones totaling more than $1.3 billion if all products
19
are registered in the licensed fields. We will also be entitled to receive up to $3.0 billion in commercial milestones based on “net sales” of vaccines in the various fields.
In addition, we are entitled to receive a 40% share of net profits from COVID-19 vaccine sales and up to low double-digit royalties of annual net sales for vaccines against influenza and the other three specified infectious disease pathogens, as well as royalties on revenues from vaccines that may be developed for pandemic preparedness.
The CSL Collaboration Agreement sets forth how CSL Seqirus and we shall collaborate to research and develop vaccine candidates. In the COVID-19 field, we will lead activities for certain regulatory filings for ARCT-154 in the US and Europe and for research and development activities of a next-generation COVID vaccine candidate. CSL Seqirus will lead and be responsible for all other research and development in COVID-19, influenza and the other fields.
Wells Fargo Credit Agreement
On April 21, 2023, our wholly-owned subsidiary, Arcturus Therapeutics, Inc. entered into a credit agreement with Wells Fargo Bank, National Association (“Wells Fargo”) whereby Wells Fargo agreed to make a $50.0 million revolving credit line available to us (as amended, the “Wells Fargo Loan”) with each Wells Fargo Loan evidenced by a revolving line of credit note (each, a “Note”). On June 26, 2024, the parties entered into Amendment No. 1 to the Wells Fargo Loan, whereby the term was extended by one year to April 2026.
Borrowings under the agreement will bear interest at a rate of 1.00% above either the Daily Simple SOFR or Term SOFR (as such terms are defined in the Wells Fargo Loan), with “SOFR” being the rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. If an Event of Default (as defined in the credit agreement) occurs, then all Wells Fargo Loans shall bear interest at a rate equal to 2.00% above the interest rate applicable immediately prior to the occurrence of the Event of Default.
The original term of the agreement is two years, with an option for one-year renewals subject to Wells Fargo approval and we furnishing to Wells Fargo a non-refundable commitment fee equal to 0.25% of the Wells Fargo Loan amount for each such renewal. There is no penalty for terminating the agreement. There is no penalty for terminating the facility prior to the maturity date of the Wells Fargo Loan. As collateral, the Company has agreed to pledge $55.0 million in cash to be held at our securities accounts with Wells Fargo Securities, LLC, an affiliate of Wells Fargo, pursuant to a security agreement.
Grant from the Biomedical Advanced Research and Development Authority
On August 31, 2022, we entered into a cost reimbursement contract (the “BARDA Contract”) with the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the Office of the Assistant Secretary for Preparedness and Response (“ASPR”) within the U.S. Department of Health and Human Services (“HHS”) to support the development of a low-dose pandemic influenza candidate based on our proprietary self-amplifying messenger RNA-based vaccine platform. The BARDA Contract is to support our non-clinical and pre-clinical development, early-stage clinical development through Phase 1, and associated drug product manufacturing, regulatory and quality-assurance activities over a period of three years. It provides for reimbursement by BARDA of our permitted costs up to $63.2 million. As of June 30, 2025, the remaining available funding net of revenue earned was $32.2 million.
Vinbiocare Agreement
During 2021, we entered into a technology license and technical support agreement and the framework drug substance supply agreement with Vinbiocare, a member of Vingroup Joint Stock Company (collectively, the “Vinbiocare License & Supply Agreements”), whereby we would provide technical expertise and support services to Vinbiocare to assist in the build out of an mRNA drug product manufacturing facility in Vietnam. We received an upfront payment in aggregate of $40.0 million as part of the Vinbiocare License and Supply Agreements. In October 2022, in association with the termination of the Vinbiocare License and Supply Agreements, we signed the Vinbiocare Support Agreement with Vinbiocare which continues Vinbiocare’s clinical obligations and reserved a portion of the original $40.0 million upfront payment received from the License and Supply Agreements to be paid over the future periods.
The Vinbiocare Support Agreement required us to pay to Vinbiocare certain limited payments, including upon the occurrence of specified events through the first quarter of 2025. Vinbiocare is also eligible to receive a single digit percentage of amounts received by Arcturus on net sales, if any, of ARCT-154 (or next-generation COVID vaccine) up to a capped amount.
General Financial Resources
A portion of our current cash balance is expected to be utilized during fiscal year 2025 to fund (i) the continued Phase 2 trial of ARCT-810, our LUNAR-OTC candidate, (ii) advances to our LUNAR-CF program in clinical trials, (iii) expenses incurred prior to customer payments under the CSL Collaboration Agreement and BARDA Contract and (iv) continued exploratory activities related to our platform and other general administrative activities.
Our future capital requirements are difficult to forecast and will depend on many factors that are out of our control. If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations will be materially and
20
adversely affected. There can be no assurance that we will be able to obtain additional needed financing on acceptable terms or at all. Additionally, equity or debt financings may have a dilutive effect on the holdings of our existing shareholders.
We expect to continue to incur additional losses in the long term, and we will need to execute on the remaining milestones within the CSL Collaboration Agreement, raise additional debt or equity financing or enter into additional partnerships to fund development. Our ability to transition to profitability is dependent on regulatory approvals and subsequent sales of KOSTAIVE, executing on milestones within the CSL Collaboration Agreement and identifying and developing other successful mRNA drug and vaccine candidates. If we are not able to achieve planned milestones or incur costs in excess of our forecasts, we will need to reduce discretionary spending, discontinue the development of some or all of our programs, which will delay part of our development programs, all of which will have a material adverse effect on our ability to achieve our intended business objectives.
Overview
The following table shows a summary of our cash flows for the six months ended June 30, 2025 and 2024:
|
|
Six Months Ended June 30, |
|
|||||
(in thousands) |
|
2025 |
|
|
2024 |
|
||
Cash provided by (used in): |
|
|
|
|
|
|
||
Operating activities |
|
$ |
(40,893 |
) |
|
$ |
(35,699 |
) |
Investing activities |
|
|
(137 |
) |
|
|
(568 |
) |
Financing activities |
|
|
469 |
|
|
|
4,591 |
|
Net decrease in cash and restricted cash |
|
$ |
(40,561 |
) |
|
$ |
(31,676 |
) |
Operating Activities
Net cash used in operating activities was $40.9 million for the six months ended June 30, 2025, compared to $35.7 million for the six months ended June 30, 2024. The increase in cash outflows was primarily driven by working capital changes, including a total decrease of $22.1 million in accrued liabilities and accounts payable due to increased vendor payments during the period. These impacts were partially offset by a $14.1 million improvement in net loss after non-cash adjustments and a $4.2 million cash inflow related to changes in prepaid and other current assets.
Investing Activities
Net cash used in investing activities of $0.1 million for the six months ended June 30, 2025, and $0.6 million for the six months ended June 30, 2024, reflected the acquisition of property and equipment.
Financing Activities
Net cash provided by financing activities was $0.5 million for the six months ended June 30, 2025, compared to $4.6 million for the six months ended June 30, 2024. The decrease was primarily driven by reduced stock option exercise activity in 2025.
Funding Requirements
We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin commercialization of our products. As a result, we will require additional capital to fund our operations in order to support our long-term plans. We believe that our current cash position will be sufficient to meet our anticipated cash requirements through at least the next twelve months, assuming, among other things, no significant unforeseen expenses and continued funding from partners at anticipated levels. We intend to seek additional capital through equity and/or debt financings, collaborative or other funding arrangements with partners or through other sources of financing when and as needed. Should we seek additional financing from outside sources, we may not be able to raise such financing on terms acceptable to us or at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to scale back or discontinue the advancement of product candidates, reduce headcount, liquidate our assets, file for bankruptcy, reorganize, merge with another entity, or cease operations.
Our future funding requirements are difficult to forecast and will depend on many factors, including the following:
21
Critical Accounting Policies and Estimates
We prepare our condensed consolidated financial statements in conformity with GAAP. As such, we make certain estimates, judgments and assumptions that we believe are reasonable, based upon information available to us. These judgments involve making estimates about the effect of matters that are inherently uncertain and may significantly impact our reported results of operations and financial condition. We describe our significant accounting policies more fully in Note 2 to our consolidated financial statements for the year ended December 31, 2024.
There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in the 2024 Annual Report.
22
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates in the United States. Due to the nature of our cash and cash equivalents, we believe that we are not subject to any material market risk exposure. We maintain an immaterial amount of foreign currency, which we do not consider to pose a material risk. We do not use derivative financial instruments.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
As required by Rule 13a-15(b) and Rule 15d-15(b) of the Exchange Act, our management, including our principal executive officer, and our principal financial and accounting officer, conducted an evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, management has concluded that as of June 30, 2025, our disclosure controls and procedures were not effective due to the material weakness in internal control over financial reporting described below.
The Company’s disclosure controls and procedures have been designed to ensure that: (i) information required to be disclosed by us in reports that we file or submit to the SEC under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in applicable rules and forms and (ii) material information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including the CEO and the CFO, as appropriate, to allow for accurate and timely decisions regarding required disclosure.
Management does not expect that our disclosure controls and procedures will prevent all error and all fraud. The effectiveness of our or any system of disclosure controls and procedures, however well designed and operated, can provide only reasonable assurance that the objectives of the system will be met and is subject to certain limitations, including the exercise of judgment in designing, implementing, and evaluating controls and procedures and the assumptions used in identifying the likelihood of future events.
Material Weakness in Internal Control over Financing Reporting Existing as of June 30, 2025
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis.
Management concluded that the following material weakness disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 continues to exist as of June 30, 2025:
Notwithstanding the identified material weakness, management does not believe that the deficiencies had an adverse effect on our reported operating results or financial condition, and management has determined that the financial statements and other information included in this report and other periodic filings present fairly in all material respects our financial condition and results of operations at and for the periods presented.
Plan for Remediation of Material Weakness
Our remediation efforts are ongoing, and we will continue our initiatives to implement measures designed to ensure that control deficiencies contributing to the material weakness are remediated, such that these controls are designed, implemented, and operating effectively. We are committed to making the necessary changes and improvements to our system of controls to address the material weakness in internal control over financial reporting described above.
Management has implemented or is in the process of implementing new or enhanced internal control procedures intended to both address the material weakness identified and strengthen our overall financial control environment, including:
23
We are in the process of implementing the remediation activities as of the date of this report and believe that upon completion, we will have strengthened our ITGCs, and controls related to accounting for collaboration arrangements to address and successfully remediate the identified material weakness. However, control weaknesses are not considered remediated until new internal controls have been operational for a period of time, are tested, and management concludes that these controls are operating effectively. We expect to complete the remediation activities in the fiscal year 2025. We will continue to monitor the effectiveness of these remediation measures, and we will make any changes to the design of this plan and take such other actions that we deem appropriate given the circumstances.
Changes in Internal Control over Financial Reporting
As required by Rule 13a-15(d) and Rule 15d-15(d) of the Exchange Act, our management, including our principal executive officer and our principal financial and accounting officer, conducted an evaluation of the internal control over financial reporting to determine whether any other changes occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Based on that evaluation, our principal executive officer and our principal financial and accounting officer concluded that there were no changes in our internal controls over financial reporting during the periods covered by this Quarterly Report on Form 10-Q that materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.
24
PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
On May 30, 2025, we initiated an arbitration against CSL Seqirus before the International Chamber of Commerce, seeking payment of a milestone under the CSL Collaboration Agreement based on the European Commission’s grant of marketing authorization for a presentation of KOSTAIVE® in the European Union. On July 25, 2025, CSL Seqirus submitted an Answer in the arbitration contending that it does not have a current obligation to pay the milestone. The arbitration is ongoing, and the parties remain committed to the ongoing success of the collaboration.
From time to time, we may be involved in various legal proceedings and subject to claims that arise in the ordinary course of business, including those related to governmental inquiries, intellectual property and commercial relationships. The subject matter of any such legal proceedings or claims are or will be highly complex and subject to substantial uncertainties. The outcome of any such proceedings or claims, regardless of the merits, are and will be inherently uncertain; therefore, assessing the likelihood of loss and any estimated damages is difficult and subject to considerable judgment.
Item 1A. Risk Factors.
Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which we strongly encourage you to review. There have been no material changes from the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Commission on March 6, 2025.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
Rule 10b5-1 Trading Arrangements
During the three months ended June 30, 2025,
25
Item 6. Exhibits.
Exhibit Index
Exhibit Number |
|
Description |
|
|
|
1.1 |
|
Controlled Equity Offering℠ Sales Agreement, dated as of December 23, 2022 by and between Cantor Fitzgerald & Co, Wells Fargo Securities, LLC and Arcturus Therapeutics Holdings Inc. Incorporated by reference to Exhibit 1.2 to Registration Statement on Form S-3 filed on December 23, 2022 (File No. 333269003). |
|
|
|
1.2 |
|
Amendment No. 1 to Controlled Equity Offering℠ Sales Agreement by and between Cantor Fitzgerald & Co, Wells Fargo Securities, LLC, William Blair & Company, L.L.C., and Arcturus Therapeutics Holdings Inc. Incorporated by reference to Exhibit 1.1 to Form 8-K filed on August 7, 2023. |
|
|
|
3.1 |
|
Certificate of Incorporation. Incorporated by reference to Annex B to the proxy statement/prospectus which forms part of the Registration Statement on Form S-4 filed on March 18, 2019 (File No. 333-230353). |
|
|
|
3.2 |
|
Certificate of Amendment, dated November 25, 2020. Incorporated by reference to Exhibit 3.1 to Form 8-K filed on November 25, 2020 (File No. 001-38942). |
|
|
|
3.3 |
|
Bylaws of Arcturus Therapeutics Holdings Inc. Incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form S-3, filed with the SEC on May 8, 2020 (File No. 333-238139). |
|
|
|
4.1 |
|
Description of Registrant’s Securities. Incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed on February 28, 2022 (File No. 001-38942). |
|
|
|
10.1† |
|
Form of Indemnification Agreement. Incorporated by reference to Exhibit 10.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 16, 2020 (File No. 001-38942). |
|
|
|
10.2† |
|
Amended and Restated 2019 Omnibus Equity Incentive Plan. Incorporated by reference Exhibit 4.3 to the Registration Statement on Form S-8 filed on August 5, 2020 (File No. 333-240397). |
|
|
|
10.3*** |
|
Amended and Restated Amendment to Development and Option Agreement, dated as of September 28, 2018, by and between CureVac AG and Arcturus Therapeutics Inc. Incorporated by reference to Exhibit 99.2 to the Company’s Report of Foreign Private Issuer on Form 6-K filed on October 1, 2018 (File No. 001-35932). |
|
|
|
10.4*** |
|
Research and Exclusive License Agreement, by and between Arcturus Therapeutics, Inc. and Synthetic Genomics, Inc., effective October 24, 2017. Incorporated by reference to Exhibit 4.8 to Form 20-F filed on May 14, 2018 (File No. 001-35932). |
|
|
|
10.5*** |
|
Research Collaboration and License Agreement, by and between Arcturus Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc., entered into as of October 26, 2015, as amended October 17, 2017 and April 20, 2018. Incorporated by reference to Exhibit 4.10 to Form 20-F filed on May 14, 2018 (File No. 001-35932). |
|
|
|
10.6*** |
|
Third Amendment to Research Collaboration and License Agreement, by and between Arcturus Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc., effective June 18, 2019. Incorporated by reference to Exhibit 10.2 to Form 8-K filed on June 20, 2019 (File No. 001- 38942). |
|
|
|
10.7*** |
|
Letter Agreement, by and between Arcturus Therapeutics, Inc. and the Cystic Fibrosis Foundation, dated May 16, 2017. Incorporated by reference to Exhibit 4.11 to Form 20-F filed on May 14, 2018 (File No. 001-35932). |
|
|
|
10.8*** |
|
Amendment No. 2 to Letter Agreement, by and between Arcturus Therapeutics, Inc. and the Cystic Fibrosis Foundation, dated August 1, 2019. Incorporated by reference to Exhibit 10.16 to Form 10-Q filed on August 14, 2019. |
|
|
|
10.9*** |
|
Development and Option Agreement, by and between Arcturus Therapeutics, Inc. and CureVac AG, dated January 1, 2018, as amended May 3, 2018. Incorporated by reference to Exhibit 4.12 to Form 20-F filed on May 14, 2018 (File No. 001-35932). |
|
|
|
10.10*** |
|
Third Amendment to Development and Option Agreement, by and between Arcturus Therapeutics, Inc. and CureVac AG, dated July 26, 2019. Incorporated by reference to Exhibit 10.20 to Form 10-Q filed on August 14, 2019 (File No. 001-38942). |
|
|
|
10.11*** |
|
License Agreement, by and between Arcturus Therapeutics, Inc., as successor-in-interest to Marina Biotech, Inc., and Protiva Biotherapeutics Inc., dated as of November 28, 2012. Incorporated by reference to Exhibit 4.14 to Form 20-F/A filed on July 10, 2018 (File No. 001-35932). |
26
|
|
|
10.12*** |
|
Patent Assignment and License Agreement, by and between Arcturus Therapeutics, Inc. and Marina Biotech, Inc., dated as of August 9, 2013. Incorporated by reference to Exhibit 4.15 to Form 20-F filed on May 14, 2018 (File No. 001-35932). |
|
|
|
10.13 |
|
Share Exchange Agreement, dated as of February 11, 2019, by and between Arcturus Therapeutics Ltd. and Arcturus Therapeutics Holdings Inc. Incorporated by reference to Exhibit 10.13 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed on March 18, 2019 (File No. 001-35932). |
|
|
|
10.14 |
|
Lease Agreement, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated October 4, 2017. Incorporated by reference to Exhibit 4.6 to Form 20-F filed on May 14, 2018 (File No. 001-35932). |
|
|
|
10.15 |
|
First Amendment to Lease Agreement, by and between Arcturus Therapeutics Holdings Inc. and ARE-SD Region No. 44, LLC dated February 1, 2020. Incorporated by reference to Exhibit 10.23 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 16, 2020 (File No. 001-38942). |
|
|
|
10.16*** |
|
Acceptance Letter, dated March 4, 2020, by and between Arcturus Therapeutics Holdings Inc. and the Economic Development Board of Singapore. Incorporated by reference to Exhibit 10.24 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 16, 2020 (File No. 001-38942). |
|
|
|
10.17† |
|
2020 Employee Stock Purchase Plan. Incorporated by reference to Exhibit 4.3 to Form S-8 filed on August 5, 2020 (File No. 333-240392). |
|
|
|
10.18 |
|
Second Amendment to Lease, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated November 13, 2020. Incorporated by reference to Exhibit 10.29 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 1, 2020 (File No. 001-38942). |
|
|
|
10.19 |
|
Third Amendment to Lease, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated February 25, 2021. Incorporated by reference to Exhibit 10.30 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 1, 2020 (File No. 001-38942). |
|
|
|
10.20 |
|
Arcturus Therapeutics Holdings Inc. Severance Policy for Executives. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on April 26, 2021 (File No. 001-38942). |
|
|
|
10.21 |
|
Lease, by and between Arcturus Therapeutics, Inc. and TPSC IX, LLC, dated September 29, 2021. Incorporated by reference to Exhibit 10.35 to Form 10-Q filed on November 9, 2021 (File No. 001-38942). |
|
|
|
10.22† |
|
Arcturus Therapeutics Holdings Inc. 2021 Inducement Equity Incentive Plan. Incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-8 filed on October 20, 2021 (File No. 333-260391). |
|
|
|
10.23† |
|
Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-8 filed on June 30, 2022. |
|
|
|
10.24*** |
|
Cost Reimbursement Contract dated August 31, 2022, by and between Arcturus Therapeutics Holdings Inc. and Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. Incorporated by reference to Exhibit 10.36 to Quarterly Report on Form 10-Q filed on November 9, 2022 (File No. 001-38942). |
|
|
|
10.25*** |
|
Study Support Agreement, dated October 31, 2022, by and between Arcturus Therapeutics, Inc. and Vinbiocare Research and Manufacture Joint Stock Company. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on November 4, 2022 (File No. 001-38942). |
|
|
|
10.26*** |
|
Collaboration and License Agreement, dated November 1, 2022, by and between Arcturus Therapeutics Holdings Inc. and CSL Limited. Incorporated by reference to Exhibit 10.38 to Quarterly Report on Form 10-Q filed on November 9, 2022 (File No. 001-38942). |
|
|
|
10.27*** |
|
Manufacturing Support Agreement Termination Letter, dated March 23, 2023, by and between Arcturus Therapeutics, Inc. and the Economic Development of Singapore. Incorporated by reference to Exhibit 10.41 to Annual Report on Form 10-K filed on March 29, 2023 (File No. 001-38942). |
|
|
|
10.28*** |
|
Credit Agreement dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.28 to Quarterly Report on Form 10-Q filed on May 9, 2023 (File No. 001-38942). |
|
|
|
27
10.29*** |
|
Security Agreement dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.29 to Quarterly Report on Form 10-Q filed on May 9, 2023 (File No. 001-38942). |
|
|
|
10.30*** |
|
Revolving Line of Credit Note dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.30 to Quarterly Report on Form 10-Q filed on May 9, 2023 (File No. 001-38942). |
|
|
|
10.31*** |
|
Amendment Number One to Collaboration and License Agreement, dated August 3, 2023, by and between Arcturus Therapeutics, Inc. and Seqirus Inc. Incorporated by reference to Exhibit 10.31 to Quarterly Report on Form 10-Q filed on November 14, 2023 (File No. 001-38942). |
|
|
|
10.32*** |
|
Amendment No. 4 to Letter Agreement, dated September 25, 2023, by and between Arcturus Therapeutics, Inc. and the Cystic Fibrosis Foundation. Incorporated by reference to Exhibit 10.32 to Quarterly Report on Form 10-Q filed on November 14, 2023 (File No. 001-38942). |
|
|
|
10.33*** |
|
Amendment Number Two to Collaboration and License Agreement, dated March 29, 2024, by and between Arcturus Therapeutics, Inc. and Seqirus Inc. Incorporated by reference to Exhibit 10.33 to Quarterly Report on Form 10-Q filed on May 8, 2024 (File No. 001-38942). |
|
|
|
10.34† |
|
Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 14, 2024 (File No. 001-38942). |
|
|
|
10.35*** |
|
First Amendment to Credit Agreement and First Amendment to Revolving Line of Credit, dated June 26, 2024, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.35 to Quarterly Report on Form 10-Q filed on August 5, 2024 (File No. 001-38942). |
|
|
|
10.36 |
|
Fifth Amendment to Lease, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated July 12, 2024. Incorporated by reference to Exhibit 10.36 to Quarterly Report on Form 10-Q filed on May 12, 2025 (File No. 001-38942). |
|
|
|
31.1* |
|
Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended. |
|
|
|
31.2* |
|
Certification by Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended. |
|
|
|
32.1** |
|
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
|
32.2** |
|
Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
|
101* |
|
The following financial statements and footnotes from the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025 formatted in Inline Extensible Business Reporting Language (Inline XBRL): |
|
|
101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
|
|
101.SCH Inline XBRL Taxonomy Extension Schema |
|
|
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase |
|
|
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase |
|
|
101.LAB Inline XBRL Taxonomy Extension Label Linkbase |
|
|
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
|
|
|
* Filed herewith.
** The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Arcturus Therapeutics Holdings Inc. under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date of this Quarterly Report, irrespective of any general incorporation language contained in such filing
*** Certain confidential portions of this exhibit have been redacted from the publicly filed document because such portions are (i) not material and (ii) would be competitively harmful if publicly disclosed.
† Management compensatory plan, contract or arrangement.
28
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
|
|
|
Date: August 11, 2025 |
By: |
/s/ Andy Sassine |
|
|
Andy Sassine |
|
|
Chief Financial Officer Principal Financial and Accounting Officer |
29
FAQ
What were ARCT's (ARCT) revenue and net loss for the quarter?
How much cash does Arcturus have on hand (ARCT)?
What material payments has Arcturus received from CSL Seqirus (ARCT)?
What regulatory approvals does KOSTAIVE (ARCT-154) have?
What government funding does Arcturus have remaining under BARDA (ARCT)?
